DAIDS SCORE Manual
Quality Management
Version 1.0-19 January 2021 Page 4 of 8
For Pharmacy and Laboratory Quality Management Plans, refer to the Pharmacy
Guidelines and Instructions for DAIDS Clinical Trials Networks and Good Clinical
Laboratory Practice Guidelines respectively.
Clinical Quality Management Plan Requirements
At minimum, DAIDS requires the CQMP to:
a. Describe roles and responsibilities of key personnel involved in developing,
implementing, and evaluating the CQMP.
b. Determine Key Indicators (KIs) for QA/QC review, including:
• Informed Consent Form (ICF) and Process
• Assessment of Understanding of ICF, as applicable
• Eligibility Criteria and Process
• Protocol-Required Tests and Procedures
• Visits/Missed Visits
• Concomitant/Prohibited Medications
• Study Product Administration/Dosing
• Adverse Events (AE), Serious Adverse Events (SAE), and DAIDS-Expedited
Adverse Events (EAE) identification and reporting
• Protocol-defined endpoints identification and reporting, as applicable.
• Source Documents, Signatures, Initials, Dates
• Investigator File Review Deficiencies
c. Describe QM Activities:
• QC review activities verify tasks were performed according to designated
instructions and/or requirements. QC is conducted in real time, immediately
after a task is performed, or at least before the next critical step of clinical
trial. These activities support compliance with ICH E6, Human Subject
Protection (HSP), protocol directives, and CRS requirements. Examples of
QC activities include:
Re-reviewing eligibility checklists before enrolling a participant onto
study and performing additional protocol procedures.
Verifying that visit checklists are completed at the end of participant
visits, before participants depart the CRS.
Re-reviewing ICF documents for accuracy and completeness before
participants depart the CRS (i.e., verify the correct version was used;
ensure all required dates, entries, and signatures are recorded; etc.).
• QA activities are conducted retrospectively, periodically, systematically, and
independently for a specified time-period, on a defined subset of a CRS’s
clinical trial-related activities and documents. QA audits function as an
independent examination for adherence to ICH E6, HSP, protocol, and all
other DAIDS and regulatory requirements. QA activities include: